These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36661670)

  • 1. Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer.
    Mäurer M; Schott D; Pizon M; Drozdz S; Wendt T; Wittig A; Pachmann K
    Curr Oncol; 2022 Dec; 30(1):261-273. PubMed ID: 36661670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients.
    Mäurer M; Pachmann K; Wendt T; Schott D; Wittig A
    Curr Oncol; 2021 Sep; 28(5):3507-3524. PubMed ID: 34590615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.
    Goodman CR; Seagle BL; Friedl TWP; Rack B; Lato K; Fink V; Cristofanilli M; Donnelly ED; Janni W; Shahabi S; Strauss JB
    JAMA Oncol; 2018 Aug; 4(8):e180163. PubMed ID: 29800954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of adjuvant radiotherapy on circulating epithelial tumor cells and circulating cancer stem cells in primary non-metastatic breast cancer.
    Schott DS; Pizon M; Pachmann U; Pachmann K; Schobert R; Wittig A; Mäurer M
    Transl Oncol; 2021 Mar; 14(3):101009. PubMed ID: 33453469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.
    Camara O; Rengsberger M; Egbe A; Koch A; Gajda M; Hammer U; Jörke C; Rabenstein C; Untch M; Pachmann K
    Ann Oncol; 2007 Sep; 18(9):1484-92. PubMed ID: 17761704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
    Pachmann K; Dengler R; Lobodasch K; Fröhlich F; Kroll T; Rengsberger M; Schubert R; Pachmann U
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):59-65. PubMed ID: 17611779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment.
    Camara O; Jörke C; Hammer U; Egbe A; Rabenstein C; Runnebaum IB; Hoeffken K; Pachmann K
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):643-7. PubMed ID: 18936973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma.
    Pachmann K; Camara O; Kroll T; Gajda M; Gellner AK; Wotschadlo J; Runnebaum IB
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1317-27. PubMed ID: 21739182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of circulating epithelial tumor cells using the Maintrac
    Gold M; Pachmann K; Kiani A; Schobert R
    Mol Clin Oncol; 2021 Oct; 15(4):201. PubMed ID: 34462657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy.
    Pachmann K; Camara O; Kohlhase A; Rabenstein C; Kroll T; Runnebaum IB; Hoeffken K
    J Cancer Res Clin Oncol; 2011 May; 137(5):821-8. PubMed ID: 20694797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse.
    Lobodasch K; Fröhlich F; Rengsberger M; Schubert R; Dengler R; Pachmann U; Pachmann K
    Breast; 2007 Apr; 16(2):211-8. PubMed ID: 17291754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy - potential markers for predicting breast cancer recurrence?
    Rothammer A; Sage EK; Werner C; Combs SE; Multhoff G
    Radiat Oncol; 2019 May; 14(1):78. PubMed ID: 31077235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Sparano J; O'Neill A; Alpaugh K; Wolff AC; Northfelt DW; Dang CT; Sledge GW; Miller KD
    JAMA Oncol; 2018 Dec; 4(12):1700-1706. PubMed ID: 30054636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
    Hepp P; Andergassen U; Jäger B; Trapp E; Alunni-Fabbroni M; Friedl TW; Hecker N; Lorenz R; Fasching P; Schneeweiss A; Fehm T; Janni W; Rack B
    Anticancer Res; 2016 Sep; 36(9):4771-6. PubMed ID: 27630326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
    Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K
    In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients.
    Pachmann K; Schuster S
    Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30380648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
    Tinhofer I; Konschak R; Stromberger C; Raguse JD; Dreyer JH; Jöhrens K; Keilholz U; Budach V
    Ann Oncol; 2014 Oct; 25(10):2042-2047. PubMed ID: 25057171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.